EGCG-Mediated Potential Inhibition of Biofilm Development and Quorum Sensing in Pseudomonas aeruginosa
Pseudomonas aeruginosa (P. aeruginosa), one of the dangerous multidrug resistance pathogens, orchestrates virulence factors production through quorum sensing (QS). Since the exploration of QS inhibitors, targeting virulence to circumvent bacterial pathogenesis without causing significant growth inhibition is a promising approach to treat P. aeruginosa infections. The present study has evaluated the anti-QS and anti-infective activity of epigallocatechin-3-gallate (EGCG), a bioactive ingredient of the traditional green tea, against P. aeruginosa. EGCG showed significant inhibitory effects on the development of biofilm, protease, elastase activity, swimming, and swarming motility, which was positively related to the production of C4-AHL. The expression of QS-related and QS-regulated virulence factors genes was also evaluated. Quantitative PCR analysis showed that EGCG significantly reduced the expression of las, rhl, and PQS genes and was highly correlated with the alterations of C4-AHL production. In-vivo experiments demonstrated that EGCG treatment reduced P. aeruginosa pathogenicity in Caenorhabditis elegans (C. elegans). EGCG increased the survival of C. elegans by 23.25%, 30.04%, and 36.35% in a dose-dependent manner. The findings of this study strongly suggest that EGCG could be a potential candidate for QS inhibition as an anti-virulence compound against bacterial infection.
Top-30
Journals
|
1
2
3
|
|
|
Frontiers in Cellular and Infection Microbiology
3 publications, 7.14%
|
|
|
Molecules
2 publications, 4.76%
|
|
|
Antibiotics
2 publications, 4.76%
|
|
|
Frontiers in Microbiology
2 publications, 4.76%
|
|
|
Biofilm
2 publications, 4.76%
|
|
|
International Microbiology
1 publication, 2.38%
|
|
|
Future Microbiology
1 publication, 2.38%
|
|
|
Marine Drugs
1 publication, 2.38%
|
|
|
Frontiers in Immunology
1 publication, 2.38%
|
|
|
Frontiers in Chemistry
1 publication, 2.38%
|
|
|
Applied Biological Chemistry
1 publication, 2.38%
|
|
|
Drug Discovery Today
1 publication, 2.38%
|
|
|
International Immunopharmacology
1 publication, 2.38%
|
|
|
Aquaculture
1 publication, 2.38%
|
|
|
Colloids and Surfaces B: Biointerfaces
1 publication, 2.38%
|
|
|
Microbial Pathogenesis
1 publication, 2.38%
|
|
|
Phytotherapy Research
1 publication, 2.38%
|
|
|
Applied Microbiology and Biotechnology
1 publication, 2.38%
|
|
|
Biochimica et Biophysica Acta - Biomembranes
1 publication, 2.38%
|
|
|
Saudi Journal of Biological Sciences
1 publication, 2.38%
|
|
|
Current Microbiology
1 publication, 2.38%
|
|
|
Bioorganic Chemistry
1 publication, 2.38%
|
|
|
Current Pharmaceutical Biotechnology
1 publication, 2.38%
|
|
|
International Journal of Molecular Sciences
1 publication, 2.38%
|
|
|
Journal of Functional Foods
1 publication, 2.38%
|
|
|
ACS applied materials & interfaces
1 publication, 2.38%
|
|
|
Journal of Food Science
1 publication, 2.38%
|
|
|
Current Issues in Molecular Biology
1 publication, 2.38%
|
|
|
BMC Microbiology
1 publication, 2.38%
|
|
|
1
2
3
|
Publishers
|
2
4
6
8
10
12
14
|
|
|
Elsevier
13 publications, 30.95%
|
|
|
MDPI
8 publications, 19.05%
|
|
|
Frontiers Media S.A.
7 publications, 16.67%
|
|
|
Springer Nature
5 publications, 11.9%
|
|
|
Taylor & Francis
2 publications, 4.76%
|
|
|
Wiley
2 publications, 4.76%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 2.38%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 2.38%
|
|
|
American Chemical Society (ACS)
1 publication, 2.38%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 2.38%
|
|
|
2
4
6
8
10
12
14
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.